Price movement over the last 24 hours
ADMA Biologics Inc vs Rent the Runway Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Rent the Runway Inc trades at $3.41 (market cap $115.40M). The key difference: ADMA Biologics Inc is far larger — about 18.5× Rent the Runway Inc's market cap. Which is the better fit depends on your goals.
| ADMA | RENT | |
|---|---|---|
Market Cap | $2.13B | $115.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $9.39 |
52-Week Low | $7.60 | $3.10 |
Enterprise Value | $2.20B | $275.50M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
RENT trades at $3.42, down 0.87% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $89.9 million, up 29.2% year-over-year, but continues to post net losses. Valuation ratios appear low with a P/E of 0.43 and P/S of 0.18, while negative equity of -$182.5 million and high debt levels pose financial risks. Recent leadership changes include the appointment of an interim CEO.
The outlook is mixed: strong revenue growth and low valuations suggest potential upside, but persistent losses, negative equity, and high leverage present significant risks. Analyst consensus is divided with 42% buy ratings, though no sell ratings exist. The stock's direction hinges on achieving profitability and managing debt.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →